[1]刘晓秋,周则卫,沈秀,等.放射增敏剂尼可胺对Wistar大鼠致畸作用的研究[J].国际放射医学核医学杂志,2013,37(2):81-83.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
　LIU Xiao-qiu,ZHOU Ze-wei,SHEN Xiu,et al.Study on teratogenicity of Nikean in Wistar rats[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):81-83.[doi:10.3760/cma.j.issn.1673-4114.2013.02.005]
点击复制

放射增敏剂尼可胺对Wistar大鼠致畸作用的研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第2期
页码:
81-83
栏目:
论著
出版日期:
2013-03-25

文章信息/Info

Title:
Study on teratogenicity of Nikean in Wistar rats
作者:
刘晓秋;  周则卫;  沈秀;  吴红英;  王德芝;  王芹
北京协和医学院中国医学科学院放射医学研究所, 天津市分子核医学重点实验室, 天津, 300196
Author(s):
LIU Xiao-qiu;  ZHOU Ze-wei;  SHEN Xiu;  WU Hong-Ying;  WANG De-zhi;  WANG Qin
Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin 300192, China
关键词:
辐射增敏药; 烟酰胺; 大鼠; Wistar; 致畸剂
Keywords:
Radiation-sensitizing agents; Niacinamide; Rats; Wistar; Teratogens
DOI:
10.3760/cma.j.issn.1673-4114.2013.02.005
摘要:
目的 探讨放射增敏剂尼可胺对Wistar大鼠的致畸毒性。方法 将Wistar受孕大鼠随机分为尼可胺高、中、低3个剂量(300、200、100 mg/kg)的给药组以及空白对照组(0.9%氯化钠注射液).大鼠于孕期第10天按1.0 ml/100g体质量连续尾静脉注射给药10d.受孕20 d处死孕鼠,检查母体妊娠与胚胎畸形情况。结果 尼可胺各剂量组孕鼠的体质量与空白对照组比较,差异无统计学意义;尼可胺各剂量组均未观察到胎鼠明显的脏器及骨骼的畸形;尼可胺各剂量组雌性和雄性胎鼠活胎体质量、尾长及体长均较空白对照组明显减少和降低。结论 尼可胺在受试剂量下存在一定的胎儿毒性,但无明显的致畸作用。
Abstract:
Objective To investigate the teratogenicity of Nikean in Wistar rats.Methods Pregnant rats were divided into 4 groups,three Nikean dosage groups (300,200,100 mg/kg) and one negative control group.Nikean or normal saline was given via caudal vein injection for 10 days from the 10 th day of gestation.Pregnant rats were killed at the 20th day of gestation,and parers and their fetuses were examined.Results Compared to the control group,there was no difference in weight of pregnant rats in three Nikean dosage groups.No abnormality was observed in skeleton and internal organs of fetuses in three Nikean dosage groups.There were significant differences between three Nikean dosage groups and control group in fetal weight,trunk length and tail length in female and male rats.Conclusion NiKeAn at the dose of 300,200,100 mg/kg showed a certain fetotoxicity but had no apparent teratogenesis in rats.

参考文献/References:

[1] Fentono BM,Lord EM,Paoni SF,et al.Enhancement of tumor per-fusion and oxygenation by carbogen and nicotinamide during sin-gle-and multifraction irradiation.Radiat Res,2000,153(1):75-83.
[2] 顾菲,刘晓秋,韩英,等.肿瘤放疗增敏药9401号的细胞毒性和体外放射增敏作用.中国辐射卫生,2006,15(4):392-393.
[3] 刘晓秋,王荣先,李美佳,等.放射增效剂9402号对小鼠小肠隐窝上皮细胞增敏作用的研究.中国辐射卫生,2007,16(1):10-11.
[4] 袁伯俊,王治乔.新药临床前安全性评价与实践.北京:军事医学科学出版社,1997:117-151.
[5] 中华人民共和国卫生部药政局.新药(西药)临床前研究指导原则汇编(药学、药理学、毒理学).北京:人民卫生出版社,1993:216-217.
[6] Yin ZL,Dahlstrom JE,Le Couteur DG,et al.Immunohistochemistry of omega class glutathione S-transferase in human tissues.J His-tochemCytochem,2001,49(8):983-987.
[7] Schmuck EM,Board PG,Whitbread AK,et al.Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants:implica-tions for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s dieases.Phamacogenet Genomics,2005,15(7):493-501.

相似文献/References:

[1]霍小东,王慧星,阎卫亮,等.血管内皮抑制素对125I近距离照射裸鼠肺癌移植瘤的增敏效应研究[J].国际放射医学核医学杂志,2016,40(5):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
　Huo Xiaodong,Wang Huixing,Yan Weiliang,et al.Sensitization effect of endostatin for 125I brachytherapy on transplanted tumor in nude mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):357.[doi:10.3760/cma.j.issn.1673-4114.2016.05.006]
[2]黄少祥,樊体强.塞来昔布对非小细胞肺癌移植瘤的辐射增敏实验研究[J].国际放射医学核医学杂志,2013,37(3):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
　HUANG Shao-xiang,FAN Ti-qiang.Radiosensitization on non-small cell lung cancer induced by celecoxib[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):150.[doi:10.3760/cma.j.issn.1673-4114.2013.03.006]
[3]李卫红,王浩,周晓靓,等.肿瘤放射治疗增敏剂研究新进展[J].国际放射医学核医学杂志,2013,37(4):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
　LI Wei-hong,WANG Hao,ZHOU Xiao-liang,et al.Radiosensitizers development and the pathways[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):233.[doi:10.3760/cma.j.issn.1673-4114.2013.04.011]
[4]李玉,董丹,阎英.肿瘤辐射增敏机制研究进展[J].国际放射医学核医学杂志,2007,31(1):48.
　LI Yu,DONG Dan,Yah Ying.The development of radiosensitizer mechanisms[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):48.
[5]顾菲,刘晓秋.肿瘤辐射增敏的分子机制[J].国际放射医学核医学杂志,2006,30(5):298.
　GU Fei,LIU Xiao-qiu.The molecular mechanism of tumor radiosensitizer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):298.
[6]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
[7]李美佳,沈瑜.烟酰胺和Carbogen气体用于肿瘤放射治疗临床应用前景[J].国际放射医学核医学杂志,1995,19(2):86.
[8]董正川,段玉清,樊赛军,等.新型辐射增敏药RRx-001[J].国际放射医学核医学杂志,2017,41(3):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
　Dong Zhengchuan,Duan YuQing,Fan Saijun,et al.A novel radiosensitizer RRx-001[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):214.[doi:10.3760/cma.j.issn.1673-4114.2017.03.011]
[9]刘晓秋,沈秀,王芹,等.尼可胺在大鼠体内的药代动力学研究[J].国际放射医学核医学杂志,2013,37(5):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]
　LIU Xiao-qiu,SHEN Xiu,WANG Qin,et al.Study on pharmacokinetics of NiKeAn in rat[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):265.[doi:10.3760/cma.j.issn.1673-4114.2013.05.003]

备注/Memo

备注/Memo:
收稿日期:2012-08-20。
基金项目:天津市科技支撑计划重点项目(项目编号:09ZCKFSH01500)
通讯作者:王芹,Email:wangqin_1005@yahoo.com.cn
更新日期/Last Update: 1900-01-01